{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Kyowa+Kirin+Co.%2C+Ltd.", "query": { "sponsor": "Kyowa Kirin Co., Ltd." }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 73, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Kyowa+Kirin+Co.%2C+Ltd.&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-09T09:37:15.337Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00346632", "title": "An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "KW-2449", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2006-06", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2024-05-17", "last_synced_at": "2026-10-09T09:37:15.337Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Princeton, New Jersey • New York, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Princeton", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00346632" }, { "nct_id": "NCT02867007", "title": "KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Cancer", "Carcinoma" ], "interventions": [ { "name": "KHK2455", "type": "DRUG" }, { "name": "Mogamulizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2016-08", "completion_date": "2019-12-15", "has_results": false, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-09T09:37:15.337Z", "location_count": 3, "location_summary": "Tampa, Florida • Albuquerque, New Mexico • Houston, Texas", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02867007" }, { "nct_id": "NCT02444793", "title": "A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "PF-05082566", "type": "DRUG" }, { "name": "KW-0761", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2015-05", "completion_date": "2017-10", "has_results": true, "last_update_posted_date": "2019-02-27", "last_synced_at": "2026-10-09T09:37:15.337Z", "location_count": 21, "location_summary": "La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02444793" }, { "nct_id": "NCT04745234", "title": "Mogamulizumab Q4week Dosing in Participants With R/R CTCL", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous T-Cell Lymphoma, Relapsed", "Cutaneous T-Cell Lymphoma Refractory" ], "interventions": [ { "name": "Mogamulizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-08-16", "completion_date": "2025-05", "has_results": false, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-09T09:37:15.337Z", "location_count": 7, "location_summary": "Duarte, California • Irvine, California • Stanford, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04745234" }, { "nct_id": "NCT05027646", "title": "Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Sancuso - Part 1", "type": "DRUG" }, { "name": "Sancuso - Part 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 134, "start_date": "2021-07-06", "completion_date": "2022-01-19", "has_results": false, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-10-09T09:37:15.337Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05027646" }, { "nct_id": "NCT02647866", "title": "Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis", "Digestive System Diseases", "Colitis, Ulcerative", "Colitis", "Gastrointestinal Diseases", "Inflammatory Bowel Diseases", "Intestinal Diseases", "Colonic Diseases", "Autoimmune Disease", "Abdominal Pain" ], "interventions": [ { "name": "KHK4083", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2016-06", "completion_date": "2018-10", "has_results": true, "last_update_posted_date": "2024-04-26", "last_synced_at": "2026-10-09T09:37:15.337Z", "location_count": 1, "location_summary": "Greenville, South Carolina", "locations": [ { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02647866" }, { "nct_id": "NCT00199342", "title": "A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage IV Melanoma" ], "interventions": [ { "name": "KW-2871", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2004-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2024-05-03", "last_synced_at": "2026-10-09T09:37:15.337Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Tampa, Florida", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00199342" }, { "nct_id": "NCT00955045", "title": "A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "istradefylline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": null, "start_date": "2002-08", "completion_date": "2003-10", "has_results": false, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-09T09:37:15.337Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00955045" }, { "nct_id": "NCT00199446", "title": "Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sleep Disorder", "Restless Legs Syndrome" ], "interventions": [ { "name": "Istradefylline (KW-6002)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2005-07", "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-09T09:37:15.337Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00199446" }, { "nct_id": "NCT01340482", "title": "A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "X-linked Hypophosphatemia" ], "interventions": [ { "name": "KRN23", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2011-04", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2024-06-18", "last_synced_at": "2026-10-09T09:37:15.337Z", "location_count": 5, "location_summary": "San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01340482" } ] }